Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) (EMANATE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02100228 |
Recruitment Status :
Completed
First Posted : March 31, 2014
Results First Posted : April 10, 2018
Last Update Posted : May 23, 2018
|
Sponsor:
Pfizer
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Supportive Care |
Condition |
Atrial Fibrillation |
Interventions |
Drug: Apixaban Drug: Parenteral heparin and/or oral Vitamin K antagonist |
Enrollment | 1500 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
---|---|---|
Arm/Group Description | Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator's judgement as per local label for the prevention of stroke and systemic embolism in participants. | Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant's sensitivity to the drug according to the investigators usual practice. |
Period Title: Overall Study | ||
Started | 753 [1] | 747 [2] |
Completed | 678 | 657 |
Not Completed | 75 | 90 |
Reason Not Completed | ||
Other | 19 | 19 |
Administrative reason | 0 | 1 |
Inclusion/Exclusion criteria not met | 12 | 16 |
Non-compliance | 0 | 3 |
Lost to Follow-up | 0 | 1 |
Withdrawal by Subject | 27 | 37 |
Adverse Event | 16 | 12 |
Death | 1 | 1 |
[1]
735 treated with Apixaban
[2]
721 treated with Usual Care
|
Baseline Characteristics
Arm/Group Title | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | Total | |
---|---|---|---|---|
Arm/Group Description | Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator's judgement as per local label for the prevention of stroke and systemic embolism in participants. | Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant's sensitivity to the drug according to the investigators usual practice. | Total of all reporting groups | |
Overall Number of Baseline Participants | 753 | 747 | 1500 | |
Baseline Analysis Population Description |
Full analysis set included all randomized participants.
|
|||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 753 participants | 747 participants | 1500 participants | |
64.7 (12.19) | 64.5 (12.76) | 64.6 (12.47) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 753 participants | 747 participants | 1500 participants | |
Female |
248 32.9%
|
250 33.5%
|
498 33.2%
|
|
Male |
505 67.1%
|
497 66.5%
|
1002 66.8%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 753 participants | 747 participants | 1500 participants | |
Hispanic or Latino |
8 1.1%
|
9 1.2%
|
17 1.1%
|
|
Not Hispanic or Latino |
100 13.3%
|
99 13.3%
|
199 13.3%
|
|
Unknown or Not Reported |
645 85.7%
|
639 85.5%
|
1284 85.6%
|
|
Race/Ethnicity, Customized
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 753 participants | 747 participants | 1500 participants | |
White |
654 86.9%
|
648 86.7%
|
1302 86.8%
|
|
Black or African American |
21 2.8%
|
20 2.7%
|
41 2.7%
|
|
Asian |
78 10.4%
|
76 10.2%
|
154 10.3%
|
|
Other |
0 0.0%
|
3 0.4%
|
3 0.2%
|
Outcome Measures
Adverse Events
Limitations and Caveats
The prioritization of outcome measures is not mentioned in the study documents (Statistical Analysis Plan and Protocol). The prioritization of outcome measures is based on team's discretion.
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Results Point of Contact
Name/Title: | Pfizer ClinicalTrials.gov Call Center |
Organization: | Pfizer, Inc. |
Phone: | 1-800-718-1021 |
EMail: | ClinicalTrials.gov_Inquiries@pfizer.com |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT02100228 |
Other Study ID Numbers: |
B0661025 CV185-267 ( Other Identifier: Alias Study Number ) 2014-001231-36 ( EudraCT Number ) EMANATE ( Other Identifier: Alias Study Number ) |
First Submitted: | February 5, 2014 |
First Posted: | March 31, 2014 |
Results First Submitted: | January 17, 2018 |
Results First Posted: | April 10, 2018 |
Last Update Posted: | May 23, 2018 |